Evidence map›Paper›PMID 32336682›Full record

ArticleHaematologica2021

Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia.

George I Gavriilidis, Stavroula Ntoufa, Nikos Papakonstantinou, Konstantia Kotta, Triantafyllia Koletsa, Elisavet Chartomatsidou, Theodoros Moysiadis, Niki Stavroyianni, Achilles Anagnostopoulos, Eleni Papadaki and 2 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

George I GavriilidisLaboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece
Stavroula NtoufaInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Nikos PapakonstantinouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Konstantia KottaInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Triantafyllia KoletsaDepartment of Pathology, Faculty of Medicine, Aristotle University, Thessaloniki, Greece
Elisavet ChartomatsidouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Theodoros MoysiadisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Niki StavroyianniHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
Achilles AnagnostopoulosHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
Eleni PapadakiDepartment of Medicine, University of Crete, Heraklion, Greece
Asterios S TsiftsoglouLaboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Centre for Research and Technology Hellas · GRAristotle University of Thessaloniki · GRG. Papanikolaou General Hospital · GRKarolinska Institutet · SEUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inflammatory cytokine stem cell factor (SCF, ligand of c-kit receptor) has been implicated as a pro-oncogenic driver and an adverse prognosticator in several human cancers. Increased SCF levels have recently been reported in a small series of patients with chronic lymphocytic leukemia (CLL), however its precise role in CLL pathophysiology remains elusive. In this study, CLL cells were found to express predominantly the membrane isoform of SCF, which is known to elicit a more robust activation of the c-kit receptor. SCF was significantly overexpressed in CLL cells compared to healthy tonsillar B cells and it correlated with adverse prognostic biomarkers, shorter time-to-first treatment and shorter overall survival. Activation of immune receptors and long-term cell-cell interactions with the mesenchymal stroma led to an elevation of SCF primarily in CLL cases with an adverse prognosis. Contrariwise, suppression of oxidative stress and the BTK inhibitor ibrutinib lowered SCF levels. Interestingly, SCF significantly correlated with mitochondrial dynamics and hypoxia-inducible factor-1a which have previously been linked with clinical aggressiveness in CLL. SCF was able to elicit direct biological effects in CLL cells, affecting redox homeostasis and cell proliferation. Overall, the aberrantly expressed SCF in CLL cells emerges as a key response regulator to microenvironmental stimuli while correlating with poor prognosis. On these grounds, specific targeting of this inflammatory molecule could serve as a novel therapeutic approach in CLL.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellStem Cell FactorCell ProliferationHumansPyrazolesPyrimidinesKITLG protein, humanPyrazolesPyrimidinesStem Cell Factor

Identifiers

PMID32336682
PMCPMC7927890
OpenAlexW3013161321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.